tetano
Editor, Senior Moderator
Am J Med Sci
. 2022 Jan 2;S0002-9629(21)00432-8.
doi: 10.1016/j.amjms.2021.12.006. Online ahead of print.
Assessing the effect of blood type on death and a novel scoring system to assess clinical course in patients with COVID-19
Katharine E Thomas[SUP] 1 [/SUP], Amber Karamanis[SUP] 2 [/SUP], Erin Dauchy[SUP] 1 [/SUP], Andrew G Chapple[SUP] 3 [/SUP], Michelle M Loch[SUP] 4 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease (COVID-19) continues to lead to worldwide morbidity and mortality. This study examined the association between blood type and clinical outcomes in patients with COVID-19 measured by a calculated morbidity score and mortality rates. The secondary aim was to investigate the relationship between patient characteristics and COVID-19 associated clinical outcomes and mortality.
Methods: Logistic regression was used to determine what factors were associated with death. A total morbidity score was constructed based on overall patient's COVID-19 clinical course. This score was modeled using Quasi-Poisson regression. Bayesian variable selection was used for the logistic regression to obtain a posterior probability that blood type is important in predicting worsened clinical outcomes and death.
Results: Neither blood type nor Rh+ status was a significant moderator of death or morbidity score in regression analyses. Increased age (adjusted Odds Ratio=3.37, 95% CI=2.44-4.67), male gender (aOR=1.35, 95% CI=1.08-1.69), and number of comorbid conditions (aOR=1.28, 95% CI=1.01-1.63) were significantly associated with death. Significant factors in predicting total morbidity score were age (adjusted Multiplicative Effect=1.45; 95% CI=1.349-1.555) and gender (aME=1.17; 95% CI=1.109-1.243). The posterior probability that blood type influenced death was only 10%.
Conclusions: There is strong evidence that blood type was not a significant predictor of clinical course or death in patients hospitalized with COVID-19. Older age and male gender led to worse clinical outcomes and higher rates of death; older age, male gender, and comorbidities predicted a worse clinical course and higher morbidity score. Race was not a significant predictor of death in our population and was associated with an increased, albeit not significant, morbidity score.
Keywords: Age; COVID19; blood type; comorbidities; gender; morbidity; mortality; scoring system.
. 2022 Jan 2;S0002-9629(21)00432-8.
doi: 10.1016/j.amjms.2021.12.006. Online ahead of print.
Assessing the effect of blood type on death and a novel scoring system to assess clinical course in patients with COVID-19
Katharine E Thomas[SUP] 1 [/SUP], Amber Karamanis[SUP] 2 [/SUP], Erin Dauchy[SUP] 1 [/SUP], Andrew G Chapple[SUP] 3 [/SUP], Michelle M Loch[SUP] 4 [/SUP]
Affiliations
- PMID: 34986364
- DOI: 10.1016/j.amjms.2021.12.006
Abstract
Background: Coronavirus disease (COVID-19) continues to lead to worldwide morbidity and mortality. This study examined the association between blood type and clinical outcomes in patients with COVID-19 measured by a calculated morbidity score and mortality rates. The secondary aim was to investigate the relationship between patient characteristics and COVID-19 associated clinical outcomes and mortality.
Methods: Logistic regression was used to determine what factors were associated with death. A total morbidity score was constructed based on overall patient's COVID-19 clinical course. This score was modeled using Quasi-Poisson regression. Bayesian variable selection was used for the logistic regression to obtain a posterior probability that blood type is important in predicting worsened clinical outcomes and death.
Results: Neither blood type nor Rh+ status was a significant moderator of death or morbidity score in regression analyses. Increased age (adjusted Odds Ratio=3.37, 95% CI=2.44-4.67), male gender (aOR=1.35, 95% CI=1.08-1.69), and number of comorbid conditions (aOR=1.28, 95% CI=1.01-1.63) were significantly associated with death. Significant factors in predicting total morbidity score were age (adjusted Multiplicative Effect=1.45; 95% CI=1.349-1.555) and gender (aME=1.17; 95% CI=1.109-1.243). The posterior probability that blood type influenced death was only 10%.
Conclusions: There is strong evidence that blood type was not a significant predictor of clinical course or death in patients hospitalized with COVID-19. Older age and male gender led to worse clinical outcomes and higher rates of death; older age, male gender, and comorbidities predicted a worse clinical course and higher morbidity score. Race was not a significant predictor of death in our population and was associated with an increased, albeit not significant, morbidity score.
Keywords: Age; COVID19; blood type; comorbidities; gender; morbidity; mortality; scoring system.